{"id":62153,"date":"2025-11-06T13:03:53","date_gmt":"2025-11-06T12:03:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/"},"modified":"2025-11-06T13:03:53","modified_gmt":"2025-11-06T12:03:53","slug":"astrazenecas-9m-and-q3-2025-financial-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/","title":{"rendered":"AstraZeneca&#8217;s 9M and Q3 2025 Financial Results"},"content":{"rendered":"<div>\n<p>\n<b>Continued strong commercial performance and unprecedented pipeline delivery in the year to date<\/b>\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20251105738625\/en\/2301168\/5\/original.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251105738625\/en\/2301168\/22\/original.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251105738625\/en\/2301168\/5\/original.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251105738625\/en\/2301168\/21\/original.jpg\"><\/a><\/p>\n<p>CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;AstraZeneca:\n<\/p>\n<p>\n<b>Revenue and EPS summary<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwpadl0 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwpadl0 bwpadr0 bwvertalignb bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>9M 2025<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwpadl0\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>% Change<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwrowaltcolor0 bwpadl0 bwwidth10 bwvertalignb bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>Q3 2025<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwrowaltcolor0 bwpadl0\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>% Change<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth10 bwvertalignb bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>$m<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>Actual<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>CER<\/b><sup>1<\/sup>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth10 bwvertalignb bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>$m<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>Actual<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>CER<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>&#8211; Product Sales<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n<i>41,035<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>9<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>9<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>14,365<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>11<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>9<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>&#8211; Alliance Revenue<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n<i>2,108<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>41<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>41<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>815<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>46<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<i>44<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nProduct Revenue<sup>2<\/sup>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n43,143\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n10\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n11\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n15,180\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n12\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n11\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCollaboration Revenue\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n93\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(14\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(15\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n11\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(81\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(82\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total Revenue<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n<b>43,236<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>10<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>11<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>15,191<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>12<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>10<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Reported EPS ($)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n<b>5.10<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>43<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>42<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>1.64<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>77<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>70<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth40\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Core<\/b><sup>3<\/sup> <b>EPS<sup> <\/sup>($)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n<b>7.04<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>15<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>15<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>2.38<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>14<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>12<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b><span class=\"bwuline\">Key performance elements for 9M 2025<\/span><\/b>\n<\/p>\n<p>\n(Growth numbers at constant exchange rates)\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nTotal Revenue up 11% to $43,236m, driven by growth in all Therapy Areas, including 16% growth in Oncology and 13% growth in R&amp;I\n<\/li>\n<li>\nGrowth in Total Revenue across all major geographic regions\n<\/li>\n<li>\nCore Operating profit increased 13%\n<\/li>\n<li>\nCore EPS increased 15% to $7.04\n<\/li>\n<li>\n16 positive Phase III readouts and 31 approvals in major regions\n<\/li>\n<\/ul>\n<p>\n<span class=\"bwuline\"><b>Pascal Soriot, Chief Executive Officer, AstraZeneca, said:<\/b><\/span>\n<\/p>\n<p>\n&#8220;The strong underlying momentum across our business through the first nine months of the year sets us up well to sustain growth through 2026 and has us on track to deliver our 2030 ambition.\n<\/p>\n<p>\nAcross our pipeline we have announced an unprecedented 16 positive Phase III trials this year, with four since our previous results including high-impact readouts for baxdrostat in hypertension and Enhertu and Datroway in breast cancer.\n<\/p>\n<p>\nWe are also delivering on our strategy to strengthen our operations in the United States to power our growth. This includes a historic agreement with the US government to lower the cost of medicines for American patients, and broadening our US manufacturing footprint having broken ground at our new $4.5bn Virginia manufacturing facility in October.&#8221;\n<\/p>\n<p>\n<b><span class=\"bwuline\">Guidance<\/span><\/b>\n<\/p>\n<p>\nAstraZeneca reiterates its Total Revenue and Core EPS guidance<sup>4<\/sup> for FY 2025 at CER, based on the average foreign exchange rates through 2024.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100 bwsinglebottom\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p class=\"bwalignc\">\n<b>Total Revenue<\/b> is expected to increase by a <b>high single-digit<\/b> percentage<br \/>\n<br \/><b>Core EPS<\/b> is expected to increase by a <b>low double-digit<\/b> percentage\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100 bwsinglebottom\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nThe Core Tax rate is expected to be between 18-22%\n<\/p>\n<p>\nIf foreign exchange rates for October 2025 to December 2025 were to remain at the average rates seen in September 2025, it is anticipated that FY 2025 Total Revenue growth and Core EPS growth would be broadly similar to the growth at CER (unchanged from the previous guidance).\n<\/p>\n<p>\n<b>Results highlights<\/b>\n<\/p>\n<p>\n<b>Table 1. Milestones achieved since the prior results announcement<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwpadl0 bwsinglebottom\" colspan=\"7\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Phase III and other registrational data readouts<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Medicine<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Trial<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Indication<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Event<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Enhertu<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDESTINY-Breast05\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHigh-risk HER2+ early breast cancer (post-neoadjuvant)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPrimary endpoint met\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Datroway<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTROPION-Breast02\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n1L TNBC for patients where IO is not an option\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDual primary endpoints met\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Imfinzi<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMATTERHORN\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nResectable gastric\/GEJ cancer\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSecondary endpoint met (OS)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nbaxdrostat\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBax24\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTreatment resistant hypertension\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPrimary endpoint met\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Fasenra<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRESOLUTE\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCOPD\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPrimary endpoint not met\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Saphnelo<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTULIP-SC\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSLE (subcutaneous)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPrimary endpoint met\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth17\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwwidth44\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwsinglebottom bwwidth17\" colspan=\"7\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Regulatory approvals<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Medicine<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Trial<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Indication<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Region<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Calquence<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nECHO\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n1L MCL\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJP\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Calquence<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nACE-LY-004\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRelapsed\/refractory MCL\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJP\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Datroway<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTROPION-Breast01\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHR+ HER2- mBC\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCN\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Enhertu<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDESTINY-Breast06\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCTx na\u00efve HER2-low and -ultralow mBC\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJP\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Imfinzi<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNIAGARA\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBladder cancer\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJP\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Imfinzi<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAEGEAN\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nResectable NSCLC\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJP\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Lynparza<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPROpel\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBRCAm mCRPC\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCN\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Tezspire<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nWAYPOINT\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nChronic rhinosinusitis with nasal polyps\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUS, EU\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Koselugo<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nKOMET\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAdult neurofibromatosis type 1\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJP, EU\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Ultomiris<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCHAMPION-NMOSD\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNMOSD\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCN\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth17\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwwidth44\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwsinglebottom\" colspan=\"7\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Regulatory submissions or acceptances* in major regions<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Medicine<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Trial<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Indication<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Region<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Enhertu<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDESTINY-PanTumour02\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPreviously treated HER2+ solid tumours\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEU\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Enhertu<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDESTINY-Gastric04\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n2L HER2+ gastric\/GEJ cancer\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEU\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Enhertu<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDESTINY-Breast09\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n1L HER2+ mBC\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUS, JP, CN\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Enhertu<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDESTINY-Breast11\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNeoadjuvant HER2+ Stage II or III breast cancer\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUS, CN\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Imfinzi<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMATTERHORN\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nResectable early-stage gastric and GEJ cancers\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEU, JP\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Imfinzi<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPOTOMAC\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHigh-risk non-muscle invasive bladder cancer\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUS, EU, JP\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Truqap<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCAPItello-281\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPTEN-deficient metastatic hormone-sensitive prostate cancer\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUS, EU\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Breztri<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nKALOS\/LOGOS\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUncontrolled asthma\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUS, EU, JP, CN\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Fasenra<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNATRON\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHES\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUS, EU, JP, CN\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Saphnelo<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTULIP-SC\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSLE (subcutaneous)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUS, EU, JP\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Saphnelo<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTULIP-1\/2, AZALEA\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSLE\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCN\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth17\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>gefurulimab<\/i>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPREVAIL\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth44\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGeneralised myasthenia gravis\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwsinglebottom bwwidth21\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nJP\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"7\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>* US, EU and China regulatory submissions denotes filing acceptance<\/i>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<span class=\"bwuline\"><b>Other pipeline updates<\/b><\/span>\n<\/p>\n<p>\nFor recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix, available on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca.com%2Finvestor-relations.html&amp;esheet=54353067&amp;newsitemid=20251105738625&amp;lan=en-US&amp;anchor=www.astrazeneca.com%2Finvestor-relations.html&amp;index=1&amp;md5=a3aff85fb7531ef49aa5f187e2e9eb5f\" rel=\"nofollow\" shape=\"rect\">www.astrazeneca.com\/investor-relations.html<\/a>.\n<\/p>\n<p>\n<b><span class=\"bwuline\">Table 2: Key elements of financial performance: Q3 2025<\/span><\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFor the<b> quarter<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwtopsingle bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>Reported<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwtopsingle bwpadl0\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Change<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwtopsingle bwrowaltcolor0 bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>Core<\/b>\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwtopsingle bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwtopsingle bwrowaltcolor0 bwpadl0\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Change<\/b>\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwtopsingle bwpadl0 bwwidth36\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nended 30 September\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>$m<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>Act<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>CER<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>$m<\/b>\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>Act<\/b>\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>CER<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth36\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nProduct Revenue\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n15,180\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n12\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n11\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n15,180\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n12\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n11\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth36\" colspan=\"1\" rowspan=\"1\">\n<p>\n* See Tables 3, 27 and 28 for medicine details of Product Revenue, Product Sales and Alliance Revenue\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCollaboration Revenue\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n11\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(81)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(82)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n11\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(81)\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(82)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth36\" colspan=\"1\" rowspan=\"1\">\n<p>\n* See Tables 4 and 29 for details of Collaboration Revenue\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTotal Revenue\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n15,191\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n12\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n10\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n15,191\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n12\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n10\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth36\" colspan=\"1\" rowspan=\"1\">\n<p>\n* See Tables 5 and 6 for Total Revenue by Therapy Area and by region\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGross Margin (%)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n82\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n+4pp\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n+4pp\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n82\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth36\" colspan=\"1\" rowspan=\"1\">\n<p>\n* Variations in Gross Margin can be expected between periods due to various factors, including fluctuations in foreign exchange rates, product seasonality and Collaboration Revenue\n<\/p>\n<p>\n* See &#8216;Reporting changes&#8217; below for the definition of Gross Margin<sup>5<\/sup>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nR&amp;D expense\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3,663\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n18\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n16\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3,550\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n16\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n14\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth36\" colspan=\"1\" rowspan=\"1\">\n<p>\n* Core R&amp;D: 23% of Total Revenue<br \/>\n<br \/>+ Accelerated recruitment year-to-date in ongoing trials<br \/>\n<br \/>+ Investments in transformative technologies such as IO bispecifics, cell therapy and radioconjugates<br \/>\n<br \/>+ Positive data read-outs for high-value pipeline opportunities that have ungated large late-stage trials<br \/>\n<br \/>+ Addition of R&amp;D projects from business development\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSG&amp;A expense\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n5,085\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(1)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(3)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3,822\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n6\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth36\" colspan=\"1\" rowspan=\"1\">\n<p>\n* Core SG&amp;A: 25% of Total Revenue\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOther operating income and expense<sup>6<\/sup>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n89\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&gt;3x\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&gt;3x\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n96\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&gt;3x\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&gt;3x\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth36\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOperating Profit\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3,583\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n70\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n64\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4,993\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n16\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n13\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth36\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOperating Margin (%)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n24\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n+8pp\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n+8pp\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n33\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n+1pp\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n+1pp\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth36\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet finance expense\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n349\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n27\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n25\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n305\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(7)\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(9)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth36\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u2212 Reduction in Core driven by lower short-term borrowing during the quarter<br \/>\n<br \/>+ Reported expense in Q3 2024 included a favourable fair value adjustment\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTax rate (%)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n22\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n21\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n+2pp\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwwidth7 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n+2pp\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth36\" colspan=\"1\" rowspan=\"1\">\n<p>\n* Variations in the tax rate can be expected between periods\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth15\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEPS ($)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1.64\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n77\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n70\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2.38\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n14\n<\/p>\n<\/td>\n<td class=\"bwrowaltcolor0 bwsinglebottom bwwidth1 bwpadr0 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwpadb3 bwwidth7 bwvertalignt\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n12\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignt bwwidth36\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"15\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>For monetary values the unit of change is percent. For Gross Margin, Operating Margin and Tax rate, the unit of change is percentage points (pp).<\/i>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"15\" rowspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"15\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>In the expense commentary above, the plus and minus symbols denote the directional impact of the item being discussed, e.g. a &#8216;+&#8217; symbol beside an R&amp;D expense comment indicates that the item increased R&amp;D expenditure relative to the prior year period.<\/i>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b><span class=\"bwuline\">Corporate and business development<\/span><\/b>\n<\/p>\n<p>\n<b>Listing harmonisation<\/b>\n<\/p>\n<p>\nAs announced on 29 September 2025 and approved by shareholders on 3 November 2025, AstraZeneca will harmonise its share listing structure to deliver a global listing for global investors in a global company. It is expected that AstraZeneca shareholders will be able to trade their interests in AstraZeneca ordinary shares across the London Stock Exchange, Nasdaq Stockholm and the New York Stock Exchange from 2 February 2026. For further details, see the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca.com%2Fcontent%2Fdam%2Faz%2FPDF%2F2025%2FCircular-and-Notice-of-General-Meeting.pdf&amp;esheet=54353067&amp;newsitemid=20251105738625&amp;lan=en-US&amp;anchor=Circular&amp;index=2&amp;md5=c5978cc978e93ef887c23926d2ff2993\" rel=\"nofollow\" shape=\"rect\">Circular<\/a> containing details of the Harmonised Listing Structure.\n<\/p>\n<p>\n<b>US investment plans<\/b>\n<\/p>\n<p>\nIn October 2025, AstraZeneca announced having broken ground on its $4.5bn manufacturing facility in Rivanna Futures, Albemarle County, Virginia. This is part of the Company&#8217;s plans to invest $50bn in US manufacturing and R&amp;D by 2030, announced in July 2025.\n<\/p>\n<p>\nThe Virginia plant is expected to create approximately 3,600 direct and indirect jobs. It will produce drug substance for AstraZeneca&#8217;s weight management and metabolic portfolio, including oral GLP-1 (AZD5004), baxdrostat, oral PCSK9 (laroprovstat) and combination small molecule products, and also antibody drug conjugates for the Oncology portfolio.\n<\/p>\n<p>\n<b>Agreement with US Government<\/b>\n<\/p>\n<p>\nIn October 2025, AstraZeneca announced a historic agreement with the US administration to lower the cost of prescription medicines for American patients. The Company voluntarily agreed to a range of measures which will enable American patients to access medicines at prices that are equalised with those available in wealthy countries.\n<\/p>\n<p>\nAs part of the agreement, AstraZeneca will provide Direct-to-Consumer sales to eligible patients with prescriptions for select products for chronic diseases.\n<\/p>\n<p>\nAstraZeneca has also reached an agreement with the US Department of Commerce to delay Section 232 tariffs for three years, enabling the Company to fully onshore medicines manufacturing so that all of its medicines sold in America are made in America.\n<\/p>\n<p>\n<b>SixPeaks<\/b>\n<\/p>\n<p>\nOn 22 October 2025, AstraZeneca, by exercise of an option, completed the acquisition of the remaining share capital of SixPeaks Bio AG (SixPeaks), following an initial investment of $15m made in Q2 2024. $170m was paid on closing, $30m to be paid after two years and up to a further $100m is payable on achievement of regulatory milestones. SixPeaks is investigating potential therapies for weight-management with the aim of preserving lean muscle mass.\n<\/p>\n<p>\n<b>Agreement with Merck on <i>Koselugo<\/i><\/b>\n<\/p>\n<p>\nIn August 2025, the contractual arrangements between AstraZeneca and Merck &amp; Co., Inc., (Merck; known as MSD outside of the US and Canada) were updated and simplified relating to the global development and commercialisation of <i>Koselugo<\/i>, an oral, selective MEK inhibitor. Under the updated arrangements AstraZeneca will fully recognise the costs, revenues and profits of <i>Koselugo<\/i> globally. Merck received an upfront payment of $150 million and will receive deferred payments totalling up to $400m. In addition, Merck is eligible to receive up to $175m in potential approval milestones and up to $235m in sales milestone payments, plus single-digit royalties based on net sales. Prior to the updated arrangements, AstraZeneca fully recognised the revenues of <i>Koselugo<\/i> but shared equally pre-tax profits and losses of the product with Merck.\n<\/p>\n<p>\n<b><span class=\"bwuline\">Sustainability highlights<\/span><\/b>\n<\/p>\n<p>\nFor the third consecutive year, TIME Magazine recognised AstraZeneca as one of the World&#8217;s Best Companies with the Company ranking at 43 out of 1,000 global companies and as the top pharmaceutical company in terms of sustainability transparency.\n<\/p>\n<p>\n<b><span class=\"bwuline\">Reporting calendar<\/span><\/b>\n<\/p>\n<p>\nThe Company intends to publish its FY and Q4 2025 results on 10 February 2026.\n<\/p>\n<p>\n<b><span class=\"bwuline\">Conference call<\/span><\/b>\n<\/p>\n<p>\nA conference call and webcast for investors and analysts will begin today, 6 November 2025, at 13:00 UK time. Details can be accessed via astrazeneca.com.\n<\/p>\n<p>\n<b><span class=\"bwuline\">Reporting changes since FY 2024<\/span><\/b>\n<\/p>\n<p>\n<b>Product Revenue<\/b>\n<\/p>\n<p>\nEffective 1 January 2025, the Group has updated the presentation of Total Revenue on the face of the Statement of Comprehensive Income to include a new subtotal &#8216;Product Revenue&#8217; representing the summation of Product Sales and Alliance Revenue.\n<\/p>\n<p>\nProduct Revenue and Collaboration Revenue form Total Revenue.\n<\/p>\n<p>\nProduct Sales and Alliance Revenue will continue to be presented separately, with the new subtotal providing additional aggregation of revenue types with similar characteristics, reflecting the growing importance of Alliance Revenue.\n<\/p>\n<p>\nFull descriptions of Product Sales, Alliance Revenue and Collaboration Revenue are included from page 152 of the Group&#8217;s <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca.com%2Fcontent%2Fdam%2Faz%2FInvestor_Relations%2Fannual-report-2024%2Fpdf%2FAstraZeneca_AR_2024.pdf&amp;esheet=54353067&amp;newsitemid=20251105738625&amp;lan=en-US&amp;anchor=Annual+Report+and+Form+20-F+Information+2024.&amp;index=3&amp;md5=6674d44645b6142392d4c2605f0c4fd2\" rel=\"nofollow\" shape=\"rect\">Annual Report and Form 20-F Information 2024.<\/a>\n<\/p>\n<p>\n<b>Gross Margin<\/b>\n<\/p>\n<p>\nEffective 1 January 2025, the Group has replaced the measure of &#8216;Product Sales Gross Margin&#8217; with the measure of &#8216;Gross Margin&#8217;. Previously, the measure excluded margin related to Alliance Revenue and Collaboration Revenue. The new measure is calculated using Gross profit as a percentage of Total Revenue, thereby encompassing all revenue categories, and is intended to provide a more comprehensive measure of total performance.\n<\/p>\n<p>\n<b><span class=\"bwuline\">Notes<\/span><\/b>\n<\/p>\n<ol class=\"bwlistdecimal\">\n<li>\nConstant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2025 vs. 2024. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.\n<\/li>\n<li>\nEffective 1 January 2025, the Group has updated its presentation of Total Revenue, adding a new subtotal of Product Revenue, the sum of Product Sales and Alliance Revenue. For further details, see Note 1: &#8216;Basis of preparation and accounting policies&#8217; in the Notes to the Interim Financial Statements.\n<\/li>\n<li>\nCore financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Tables 9 and 10 in the Financial Performance section of this document.\n<\/li>\n<li>\nThe Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary statements section regarding forward-looking statements at the end of this announcement.\n<\/li>\n<li>\nEffective 1 January 2025, the Group has updated its presentation of Gross Margin. For further details, see Note 1: &#8216;Basis of preparation and accounting policies&#8217; in the Notes to the Interim Financial Statements.\n<\/li>\n<li>\nIncome from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, is recorded in Other operating income and expense in the Group&#8217;s financial statements.\n<\/li>\n<\/ol>\n<p>\nTo read AstraZeneca&#8217;s 9M and Q3 2025 Financial Results press release in full, click <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca.com%2Fmedia-centre%2Fpress-releases%2F2025%2F9m-and-q3-2025-results.html&amp;esheet=54353067&amp;newsitemid=20251105738625&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=874283baac5b0b589a24d4cb4e3f0098\" rel=\"nofollow\" shape=\"rect\">here<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nGlobal Media Relations team<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#108;&#116;o:&#x67;&#x6c;&#x6f;&#x62;&#97;&#108;-m&#x65;&#x64;&#x69;&#97;&#116;&#101;am&#x40;&#x61;&#x73;&#116;&#114;az&#x65;&#x6e;&#x65;&#x63;&#97;&#46;co&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x67;l&#x6f;b&#x61;&#108;&#x2d;&#109;e&#x64;i&#x61;&#116;&#x65;&#97;&#x6d;&#64;a&#x73;t&#x72;&#97;&#x7a;&#101;&#x6e;&#x65;c&#x61;&#46;&#x63;&#111;&#x6d;<\/a><br \/>+44 (0)1223 344 800\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Continued strong commercial performance and unprecedented pipeline delivery in the year to date CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;AstraZeneca: Revenue and EPS summary \u00a0 9M 2025 % Change Q3 2025 % Change \u00a0 $m Actual CER1 $m Actual CER &#8211; Product Sales 41,035 9 \u00a0 9 \u00a0 14,365 11 \u00a0 9 \u00a0 &#8211; Alliance Revenue 2,108 41 \u00a0 &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62153","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AstraZeneca&#039;s 9M and Q3 2025 Financial Results - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca&#039;s 9M and Q3 2025 Financial Results - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Continued strong commercial performance and unprecedented pipeline delivery in the year to date CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;AstraZeneca: Revenue and EPS summary \u00a0 9M 2025 % Change Q3 2025 % Change \u00a0 $m Actual CER1 $m Actual CER &#8211; Product Sales 41,035 9 \u00a0 9 \u00a0 14,365 11 \u00a0 9 \u00a0 &#8211; Alliance Revenue 2,108 41 \u00a0 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-06T12:03:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251105738625\/en\/2301168\/22\/original.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrazenecas-9m-and-q3-2025-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrazenecas-9m-and-q3-2025-financial-results\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AstraZeneca&#8217;s 9M and Q3 2025 Financial Results\",\"datePublished\":\"2025-11-06T12:03:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrazenecas-9m-and-q3-2025-financial-results\\\/\"},\"wordCount\":1952,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrazenecas-9m-and-q3-2025-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251105738625\\\/en\\\/2301168\\\/22\\\/original.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrazenecas-9m-and-q3-2025-financial-results\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrazenecas-9m-and-q3-2025-financial-results\\\/\",\"name\":\"AstraZeneca's 9M and Q3 2025 Financial Results - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrazenecas-9m-and-q3-2025-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrazenecas-9m-and-q3-2025-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251105738625\\\/en\\\/2301168\\\/22\\\/original.jpg\",\"datePublished\":\"2025-11-06T12:03:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrazenecas-9m-and-q3-2025-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrazenecas-9m-and-q3-2025-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrazenecas-9m-and-q3-2025-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251105738625\\\/en\\\/2301168\\\/22\\\/original.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251105738625\\\/en\\\/2301168\\\/22\\\/original.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astrazenecas-9m-and-q3-2025-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca&#8217;s 9M and Q3 2025 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca's 9M and Q3 2025 Financial Results - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca's 9M and Q3 2025 Financial Results - Pharma Trend","og_description":"Continued strong commercial performance and unprecedented pipeline delivery in the year to date CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;AstraZeneca: Revenue and EPS summary \u00a0 9M 2025 % Change Q3 2025 % Change \u00a0 $m Actual CER1 $m Actual CER &#8211; Product Sales 41,035 9 \u00a0 9 \u00a0 14,365 11 \u00a0 9 \u00a0 &#8211; Alliance Revenue 2,108 41 \u00a0 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/","og_site_name":"Pharma Trend","article_published_time":"2025-11-06T12:03:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251105738625\/en\/2301168\/22\/original.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AstraZeneca&#8217;s 9M and Q3 2025 Financial Results","datePublished":"2025-11-06T12:03:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/"},"wordCount":1952,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251105738625\/en\/2301168\/22\/original.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/","url":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/","name":"AstraZeneca's 9M and Q3 2025 Financial Results - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251105738625\/en\/2301168\/22\/original.jpg","datePublished":"2025-11-06T12:03:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251105738625\/en\/2301168\/22\/original.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251105738625\/en\/2301168\/22\/original.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/astrazenecas-9m-and-q3-2025-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca&#8217;s 9M and Q3 2025 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62153"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62153\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}